Market News

Global Cell and Gene Therapy Market: Key Developments

In January 2022, Amgen, a U.S. based multinational biopharmaceutical company, and Generate Biomedicines, a therapeutics company, announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities. As part of the research agreement collaboration, Amgen would pay US$ 50 billion in upfront funding for the initial five programs with a potential transaction value of US$ 1.9 billion plus future royalties. For each program, Amgen would pay up to US$ 370 billion in future milestones.

In June 2021, CyGenica, a biotechnology company, announced that it had raised US$ 1.4 billion in a seed fund investment round, led by the global venture capital investor SOSV, a non-governmental organization. The funding round would accelerate the validation of CyGenica's proprietary technology for safe, targeted, and affordable intercellular drug delivery. The investment would accelerate the development of disruptive drug delivery technology in the advancement of therapeutics for cancer and rare diseases to improve patients’ health and quality of life.

In March 2021, Amgen Inc., a U.S. based multinational biopharmaceutical company, and Rodeo Therapeutics Corporation, a biotechnology company, announced an agreement under which Amgen would acquire Rodeo, which develops small-molecule therapies designed to promote regeneration and repair of multiple tissues. The agreement would help the company in expansion to develop therapeutics for patients using Rodeo's 15-PGDH (a prostaglandin-degrading enzyme) program with Amgen's inflammation portfolio.

In March 2021, the U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to or whose disease has returned after at least four prior lines (different types) of therapy. Abecma is a cell-based gene therapy approved by the FDA for the treatment of multiple myeloma. Multiple myeloma is an uncommon type of blood cancer in which abnormal plasma cells build up in the bone marrow and form tumors in several bones of the body. This disease keeps the bone marrow from making enough healthy blood cells, which can result in low blood counts.

In January 2021, Biogen Inc., a multinational biotechnology company, announced that it had entered into a collaboration with two U.S.-based biotechnology companies, Atalanta Therapeutics and Genentech, to co-develop RNAi therapeutics for the treatment of neurodegenerative central nervous system (CNS) disorders such as Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease.